COMMUNIQUÉS West-GlobeNewswire

MITHRA COMPLETES RECRUITMENT FOR ADDITIONAL ESTELLE® SAFETY STUDY
21/06/2017
PRESS RELEASE MITHRA COMPLETES RECRUITMENT FOR ADDITIONAL estelle® SAFETY studY Safety study is part of the development of Estelle®, Mithra's combined oral contraceptive candidate Aim of the study is to analyze a broad [...]
Novo Nordisk receives positive 17-2 vote from FDA Advisory Committee that Victoza® provides substantial evidence of cardiovascular risk reduction in patients with type 2 diabetes
20/06/2017
Bagsværd, Denmark, 20 June 2017 - Novo Nordisk today announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the US Food and Drug Administration (FDA) has completed its meeting regarding the [...]
Galapagos increases share capital through warrant exercises
20/06/2017
Mechelen, Belgium; 20 June 2017, 22.00 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from warrant exercises. Galapagos issued 52,030 new ordinary [...]
Oriola Corporation starts repurchase of its own class B shares in connection with the company's incentive schemes
20/06/2017
Oriola Corporation Stock Exchange Release 20 June 2017 18.00 Oriola Corporation starts repurchase of its own class B shares in connection with the company's incentive schemes The Board of Directors of Oriola Corporation [...]
New Data Reveal Medtronic CRT Devices Improve Therapy Delivery and Reduce Healthcare Costs
20/06/2017
Data Presented at EUROPACE 2017 Reinforce Cost and Outcome Benefits of Exclusive EffectivCRT(TM) and AdaptivCRT(TM) Algorithms, Along with Improved Device Longevity DUBLIN and VIENNA - June 20, 2017 - Medtronic plc ( [...]
The Jackson Laboratory and Crown Bioscience Announce Global Pre-Clinical Research Agreement
20/06/2017
BAR HARBOR, Maine and SANTA CLARA, Calif., June 20, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience (CrownBio), a wholly owned subsidiary of Crown Bioscience International (TWSE: ticker 6554), and The Jackson Laboratory (JAX [...]
Holaira Announces Company Name Change to Nuvaira
20/06/2017
Company Adds Shane Gleason to Executive Team MINNEAPOLIS, June 20, 2017 (GLOBE NEWSWIRE) -- Holaira , a developer of medical devices to treat obstructive lung diseases, today announced that it has changed its name to [...]
The Jackson Laboratory et Crown Bioscience annoncent un accord mondial de recherche préclinique
20/06/2017
BAR HARBOUR (Maine) et SANTA CLARA (Californie), le 20 juin 2017 (GLOBE NEWSWIRE) - Crown Bioscience (CrownBio), filiale en propriété exclusive de Crown Bioscience International (TWSE : symbole boursier 6554) et The [...]
Holaira annonce le changement de dénomination de la société pour devenir Nuvaira
20/06/2017
Shane Gleason joint l'équipe de direction de la société MINNEAPOLIS, le 20 juin 2017 (GLOBE NEWSWIRE) - Holaira , développeur de dispositifs médicaux destinés à traiter les maladies pulmonaires obstructives, a annoncé [...]
Helsinn Group Announces Upcoming Presentation of Phase III data in NEPA (netupitant/palonestron) at MASCC/ISOO Congress in Washington DC
20/06/2017
Helsinn Group Announces Upcoming Presentation of Phase III data in NEPA (netupitant/palonestron) at MASCC/ISOO Congress in Washington DC Data demonstrates the non-inferiority of NEPA versus an aprepitant (APR)/ [...]
Nokia launches portfolio of digital health products designed to inspire people to take control of their health
20/06/2017
Nokia expands in digital health; company announces largest line of connected consumer health products New products include Nokia Body BMI Wi-Fi connected scale, Nokia BPM+ soft-cuff blood pressure monitor, new Nokia [...]
Galapagos' R&D Update 2017: rapidly advancing our product candidates
20/06/2017
Filgotinib Darwin 3: improved activity, consistent safety parameters for filgotinib Ph2 studies initiated in 6 new indications Cystic fibrosis Three different triple combos in development Successful completion of Ph1 [...]
Novartis RTH258 (brolucizumab) demonstrates robust visual gains in nAMD patients with a majority on a 12-week injection interval
20/06/2017
RTH258 achieved the primary efficacy endpoint of non-inferiority to aflibercept in mean change in BCVA from baseline to week 48[1],[2] in two head-to-head pivotal Phase III studies[3],[4] 57% and 52% of patients [...]
Novartis real world study shows almost half of chronic urticaria patients are not receiving any treatment despite significant disease burden
20/06/2017
Urgent need to improve management of chronic urticaria (CU) - a disease that causes itchy, persistent hives and swelling which last more than 6 weeks or recur over months or years - highlighted by study of over 3,700 [...]
argenx receives second preclinical milestone payment in collaboration with LEO Pharma
20/06/2017
June 20, 2017 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the [...]
NEOVACS ANNONCE LA FIN DU RECRUTEMENT DES PATIENTS POUR SON ETUDE CLINIQUE DE PHASE IIB DANS LE TRAITEMENT DU LUPUS
20/06/2017
NEOVACS ANNONCE LA FIN DU RECRUTEMENT DES PATIENTS POUR SON ETUDE CLINIQUE DE PHASE IIB DANS LE TRAITEMENT DU LUPUS Perspective de publication des résultats cliniques au cours du deuxième trimestre 2018 Paris et Boston [...]
NEOVACS ANNOUNCES THE COMPLETION OF PATIENT ENROLLMENT IN PHASE IIB CLINICAL STUDY OF IFNalpha KINOID IN LUPUS
20/06/2017
NEOVACS ANNOUNCES THE COMPLETION OF PATIENT ENROLLMENT IN PHASE IIB CLINICAL STUDY OF IFNalpha KINOID IN LUPUS Company Expects the Availability of Results from the Study in Q2 2018 Paris and Boston, June 20, 2017 - 7:00 [...]
Takeda and TiGenix announce that Swissmedic has accepted for review the file on Cx601 for the treatment of complex perianal fistulas in Crohn's disease patients
20/06/2017
PRESS RELEASE Takeda and TiGenix announce that Swissmedic has accepted for review the file on Cx601 for the treatment of complex perianal fistulas in Crohn's disease patients Pfäffikon, SZ, June 20, 2017, and Leuven, [...]
Takeda et TiGenix annoncent que Swissmedic a accepté la demande d'évaluation relative au Cx106 pour le traitement des fistules périanales complexes chez les patients atteints de la maladie de Crohn.
20/06/2017
COMMUNIQUÉ DE PRESSE Takeda et TiGenix annoncent que Swissmedic a accepté la demande d'évaluation relative au Cx106 pour le traitement des fistules périanales complexes chez les patients atteints de la maladie de Crohn [...]

Pages